Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma

Clinical Trial ID NCT01199718

Rank	Title	Journal	Year	PubWeight™‹?›
1	Restoration of CFTR function in patients with cystic fibrosis carrying the F508del-CFTR mutation.	Autophagy	2014	1.21
2	Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling.	Leukemia	2013	1.02
3	The protein kinase 2 inhibitor CX-4945 regulates osteoclast and osteoblast differentiation in vitro.	Mol Cells	2013	0.80
4	Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-κB.	Oncotarget	2016	0.77